The Challenge
The creation of a new pharmaceutical manufacturing plant is fraught with complexities, especially when considering the stringent requirements set forth by the FDA. Meeting these exacting standards is crucial to the success and legal operation of any pharmaceutical facility. In a greenfield project, the challenges intensify as processes, workflows, and structures must all harmonise without pre-existing conditions to guide them. For this particular project, the requirement was to ensure that every component of the plant's build adhered to FDA validation processes from inception to execution.
The Solution
Recognising these challenges, Adyantrix initiated a comprehensive BIM strategy with a focus on integrating model-based Quality Assurance (QA) throughout the project's lifecycle. The use of Building Information Modeling (BIM) allowed for a seamless integration of design, execution, and compliance requirements, thereby optimising the project's timelines and reducing potential for errors.
Our team utilised advanced 3D modelling techniques to create a detailed digital representation of the pharmaceutical plant, encompassing everything from structural elements to mechanical, electrical, and plumbing systems. These models were built in accordance with FDA guidelines, allowing stakeholders to visualise compliance at every stage.
A significant component of our strategy was the deployment of clash detection and coordination services. By identifying potential conflicts between various systems early in the design phase, we were able to address issues that could interfere with FDA validation processes and cause costly delays.
Furthermore, our BIM models were instrumental in facilitating a model-based QA process. This innovative approach not only ensured compliance with FDA regulations but also provided a dynamic platform for documenting and managing quality checks throughout construction. By embedding compliance data within the BIM model itself, we enabled ongoing monitoring and rapid adjustments, ensuring that the project stayed on track and fully compliant.
Key Results
The project culminated in the successful construction of a fully compliant pharmaceutical manufacturing plant, meeting all FDA validation requirements. By leveraging BIM-driven QA processes, we helped the client minimize errors and significantly reduce the overall project timeline by 25% compared to industry averages in similar projects.
The integration of a model-based approach also provided the client with enhanced visibility into project stages, enabling better decision-making and proactive issue resolution. This resulted in a smoother handover process, reducing the post-construction modification requirements by 40%.
Ultimately, our BIM solutions not only ensured regulatory compliance but also set a benchmark for efficiency in pharmaceutical plant design and construction, offering a replicable model for future projects in the sector.
Technical Approach
The BIM strategy was structured to align directly with the FDA's current Good Manufacturing Practice (cGMP) regulations and the ISPE Baseline Guide for Commissioning and Qualification (C&Q), which define the documentation and traceability requirements pharmaceutical facilities must satisfy before they can be commissioned and licensed for production.
The authoring environment was Autodesk Revit, configured with a pharmaceutical-specific shared parameter schema that embedded qualification classification data directly against model elements. Every major system — HVAC, process water, clean steam, compressed air, and utilities distribution — was tagged at component level with attributes including the system's qualification category (Design Qualification, Installation Qualification, Operational Qualification — DQ/IQ/OQ), the responsible engineering discipline, and the applicable FDA 21 CFR Part reference.
Key technical decisions included:
- ISO 19650-compliant common data environment using Autodesk BIM 360, with access controls configured to match the client's document control procedures, ensuring that model revisions followed the same approval gates as traditional engineering drawings
- Navisworks-based clash detection executed at two-week intervals across structural, architectural, MEP, and process systems disciplines, generating clash reports tagged with severity classifications aligned to the FDA's cGMP risk tiering framework
- Solibri Model Checker rule sets custom-authored to verify pharmaceutical-specific design requirements — including minimum aisle clearances for GMP access, segregation of classified and unclassified areas, and pressure cascade compliance between adjacent clean rooms — automatically across every model revision
- IFC export workflows configured to produce structured data packages for handover to the client's validation management system (VMS), enabling the qualification team to trace each physical asset back to its as-built BIM representation without manual transcription
- Dynamo automation scripts used to generate Installation Qualification punch-list templates directly from the model, pre-populated with asset tag numbers, specification references, and installation check criteria
Implementation Highlights
The engagement was structured across four principal phases, each designed to produce a discrete compliance deliverable that fed directly into the FDA validation package.
Design Qualification (DQ) Phase: The initial BIM models were developed to LOD 300 in parallel with the User Requirements Specification (URS) and Functional Design Specification (FDS) documents. A formal BIM-to-URS traceability matrix was produced, mapping every major model element to the relevant URS requirement. This matrix became the foundation of the DQ report, demonstrating to the FDA that the design as modelled satisfied each stated requirement — a process that would have required weeks of manual cross-referencing under a traditional 2D documentation approach.
Construction Coordination and IQ Preparation: As detailed design progressed, models were developed to LOD 400 for critical systems including clean utility distribution, HVAC serving classified manufacturing areas, and process drainage. Clash detection during this phase resolved over 180 hard clashes across the MEP disciplines — each of which, if left until construction, would have required an engineering change order with associated revalidation implications. The coordinated model was used to generate as-built IQ documentation templates prior to construction completion, reducing the IQ documentation burden on the commissioning team substantially.
Operational Qualification Support: BIM model data was exported in structured IFC format and imported into the client's validation management system, enabling OQ protocol writers to reference exact equipment positions, flow paths, and instrument locations from the model rather than conducting manual site surveys. This reduced the time required to draft OQ protocols for each system by an estimated 40%.
Handover and FM Integration: The final as-built model was delivered with a full COBie data export, providing the client's facilities management team with a structured asset register linked to every piece of installed equipment. For a pharmaceutical facility where ongoing cGMP compliance requires complete equipment lifecycle traceability, the value of having this data structured and accessible from day one was considerable.
Measurable Outcomes
The BIM-led approach delivered measurable improvements against every benchmark established at project inception:
- Project timeline reduced by 25% compared to the industry average for comparable greenfield pharmaceutical facilities, attributed primarily to clash resolution occurring in the design phase and validation documentation being generated directly from the model
- Post-construction modification requirement reduced by 40%, with the vast majority of design conflicts resolved digitally before any physical installation took place
- FDA validation package completeness at first submission was assessed by the client's regulatory affairs team as the most complete first-submission package they had produced on any facility project — attributed directly to the model-based traceability approach
- IQ documentation preparation time was reduced by an estimated 35% versus the client's previous facility project, where all installation qualification records had been compiled manually from 2D drawings
- Zero critical non-conformances were identified during the FDA pre-approval inspection of the facility, compared to an industry average of three to five critical findings on comparable first inspections
- Asset data completeness at handover was recorded at 96.4%, with the remaining 3.6% comprising late-addition minor components that were captured in a supplementary COBie submission within thirty days of handover
Lessons Learned
This project deepened our understanding of the specific intersection between BIM methodology and pharmaceutical regulatory compliance in ways that have since informed our practice standards for all regulated industry engagements.
Regulatory traceability must be designed into the BIM framework at the start, not retrofitted. On this project, the decision to embed qualification classification and regulatory reference attributes directly into the Revit shared parameter schema from the outset — rather than relying on a separate linked database — proved pivotal. Teams who attempt to layer compliance metadata onto a model that was not structured to carry it inevitably encounter data integrity issues that create validation risk.
The BIM model is a living validation document, not just a construction coordination tool. A common misperception is that BIM's value in pharmaceutical construction ends at clash detection. On this project, the model's greatest contribution to schedule and cost came in the qualification phases — DQ traceability, IQ template generation, and OQ protocol support. Clients who scope BIM services purely around construction coordination miss the largest portion of the regulatory value.
Engaging the validation manager as a BIM stakeholder from project outset is essential. In earlier engagements, the validation team would receive the BIM deliverables late in the project, often requiring significant rework of data formatting to meet VMS import requirements. On this project, the validation manager participated in BIM execution plan reviews from the start, ensuring the IFC export schema and COBie structure were configured to their exact import requirements before any modelling began.
Speak with our BIM Consulting team at Adyantrix to find out how we can support your next project.
Work with Adyantrix
If you are looking to tackle a similar challenge, Adyantrix has the expertise to help across the full project lifecycle. Our BIM consulting practice covers BEP authoring, ISO 19650 strategy, and CDE implementation. Our clash detection & coordination practice covers multidisciplinary coordination and conflict resolution. Our QA & testing practice covers automated testing, performance, and security QA. Our 3D visualisation & rendering practice covers photorealistic renders, walkthroughs, and CGI for AEC. Get in touch to discuss your requirements — no commitment required.
